Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

The PHIDR healthy tissue database and repository will guide T Cell Receptor (TCR)-based immune therapy development to disease-specific targets by enabling developers to identify HLA/peptide complex targets found on healthy tissues. By screening potential target candidates against PHIDR, developers can confidently select, qualify, and focus efforts on those biomarker targets that minimize off-target or bystander effects.

The PHIDR database is representative of the full healthy human immunopeptidome as it includes HLA/peptide complexes expressed on multiple tissue samples from all over the body, with a focus on the vital organs. In addition to the peptide database, PHIDR includes a repository of matched cryopreserved tissue samples that enable complimentary orthogonal target validation techniques, including proteomics-based target quantification, genomics, and transcriptomics, on an as-needed basis.

For nearly 40 years, LifeNet Health has advanced medicine through the life-changing power of organ and tissue donation. Thanks to selfless donors, scientific discovery is advanced.

LifeNet Health LifeSciences has accelerated preclinical research and discovery through its growing portfolio of primary human cells and biospecimens for solutions that expedite research and allow the scientific community to develop and enhance new, safe therapies and medical breakthroughs.

"We are excited to offer access to the PHIDR database and repository to collaborators through our Pure MHC Solutions contract research arm," said Pure MHC President Kris Looney. "We could not have successfully built this resource without our collaborators at LifeNet Health. To be able to develop such a valuable resource for therapeutic development aligns nicely with LifeNet Health's mission to help patients live longer, healthier, and enjoy more active lives."

"We are proud to partner with Pure MHC and congratulate them on achieving success in their research efforts. Thanks to selfless donors, LifeNet Health is able to offer partners more than 40 types of biospecimens for research with over 200 protocols in place to meet the individual needs of researchers advancing scientific discovery," said Louis Dias, Vice President and General Manager of LifeNet Health LifeSciences. "The LifeNet Health LifeSciences team provides access to rare patient disease populations and enables researchers to unlock discoveries faster and with greater precision - offering the hope of new therapies to patients in need."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider - committed to advancing science, accelerating discovery, and optimizing outcomes. Leading the way in human in vitro biology, LifeSciences' game-changing innovations, currently under development, include models for the metabolic disease and oncology therapeutic areas and their related tools. For more information, go to www.LNHLifeSciences.org.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Patent and Trademark

Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals

AUSTIN, Texas -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEOx1™ Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Sublingual delivery has emerged as a viable route of administration for vaccines and medications for pain, cardiovascular, allergy, seizure, sedation and emesis. The sublingual route avoids first pass metabolism and provides rapid systemic uptake into the body providing advantages over traditional oral medications.

Zeteo's latest innovations expand its ZEOx1 Hydra™ sublingual delivery device family that include configurations for mono-dose disposable and mono-dose reloadable dispensers for vaccines, drugs, biopharmaceuticals, biologics and botanical liquid formulations. "We see expanding demand for metered dose sublingual delivery devices that are easy to use, convenient to carry, deliver a precise dose and can be self-administered," said Timothy Sullivan, President of Zeteo Biomedical.

Zeteo's delivery device technology and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value added, patient-centric products benefit the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical or biotech manufacturer. Zeteo's delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.

About Zeteo Biomedical LLC

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Patent and Trademark

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

AUSTIN, Texas -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.

In addition to positive news received by the EPO, Heparinex is excited to announce that it has created a new class of sugar polymers, sulfated hepbiuronic acid (sHBA) that mimic some, but not all, of the desirable activities of heparin, a drug employed to treat many diseases including the fight against severe COVID-19 and influenza. These novel patent-pending drug candidates can quell the initiation of inflammation, but do not inhibit blood coagulation, thus can be used to protect organs such as the lungs, heart, and kidneys that are often damaged by the body's own defenses during disease without the risk of bleeding. The sHBA should be a useful addition to the arsenal of drugs currently dispensed to treat hyper-inflammation spawned by infectious, cardiovascular, and auto-immune diseases.

Heparosan conjugation was developed by Presidential Professor Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center (OUHSC) and includes a robust U.S. and international patent portfolio. "Our goal is to decipher and harness the natural 'sugar codes' in the body in more selective, customized fashion to target diseases and reduce side effects. We are excited by the possibilities for better medicines", said DeAngelis. He was named as one of the most influential researchers in the world according to a study led by an investigator at Stanford University and published in PLOS Biology.

About Caisson Biotech, LLC

Caisson Biotech, LLC is a collaboration driven biotechnology company specializing in the development of heparosan polymers to improve therapeutic drug delivery and performance. Caisson's HEPtune® technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist. Visit: https://caissonbiotech.com/.

Caisson Biotech is a subsidiary of Heparinex, LLC.

About Heparinex, LLC

Heparinex, LLC is a biopharmaceutical company focused on the novel recombinant synthesis of sugar-based compounds for markets including anticoagulation, inflammation, and cancer treatment. Dr. Paul DeAngelis originally discovered and patented Heparinex's core technology platforms of proprietary carbohydrate production. Visit: https://heparinex.com/.

Heparinex and Caisson are funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/

Related link: https://caissonbiotech.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome

CARY, N.C. -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

"We are honored to receive these very important designations for our lead drug for Kabuki Syndrome. The decision validated the urgency and need for treatment of this devastating disease for which there are no FDA-approved therapies," said Dr. Athanasios (Thanos) Maroglou, co-founder, President and CEO of Rescindo. "With RSC-57 being a repurposed drug with a large established safety profile, we hope to proceed with clinical trials rapidly after the completion of our pre-IND package and guidance from the FDA."

Orphan Drug Designation is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the United States. Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.

Rare Pediatric Disease Designation is granted by the FDA in the case of serious or life-threatening diseases affecting fewer than 200,000 people in the United States, primarily those 18 years of age and younger. The sponsor of a drug with Rare Pediatric Disease Designation may, upon marketing approval, qualify for receipt of a priority review voucher applicable to a subsequent marketing application, which voucher is fully transferable.

About Kabuki Syndrome

Kabuki Syndrome is a rare developmental disorder characterized by intellectual disability, muscle hypotonia, distinctive facial features, short stature, immune deficiency and malformations of the cardiac, renal, gastrointestinal, and/or skeletal systems. Typically diagnosed during early childhood, it is possible to identify KS as early as infancy based on characteristic facial features and associated organ malformations.

The global prevalence of KS is estimated at 1:32,000 births, although its incidence is likely underestimated, as judged by the acceleration of new cases now that genome sequencing is becoming more broadly available. At present, KS has no cure.

About Rescindo Therapeutics Inc.

Rescindo Therapeutics is drug discovery and development company focused on rare genetic diseases to improve peoples' lives.

Rescindo Therapeutics Inc. was founded in 2015 by Dr. Athanasios Maroglou and Dr. Nicholas Katsanis with an objective to discover and develop new drugs for children with rare genetic diseases. Using a novel approach that combines genetics, molecular biology, and high throughput use of model organisms, we accelerate the discovery of new therapies. Together with our academic, private sector partners, and patient advocacy groups, we are working toward bringing new treatments for life-threatening disorders.

Learn more at: https://www.rescindotherapeutics.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0214s2p-rescindo-300dpi.jpg

Related link: https://www.rescindotherapeutics.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Advertising and Marketing, Business, Drugs and Pharmaceuticals, Free News Articles

Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson

AUSTIN, Texas -- Kalyagen™ is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN®, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"The link between a lower number of circulating stem cells and the development of age-related problems has been well documented, and increasing the number of circulating stem cells has also been well documented to enhance tissue repair and improve the course of many age-related conditions," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "Stemregen can indeed help to stem the tide of time, and the campaign asks the question "what does Stem the Tide of Time mean to you?"

The campaign, designed to increase awareness of STEMREGEN®, is launching to coincide with Marques Johnson's annual birthday dunk.

"Eleven years and 27,000 minutes of running and jumping up and down NBA floors has taken its toll on my body," said Marques Johnson. "'Stem the Tide of Time' for me means that I can slow or stop the onset of stiffness and soreness so I can participate in the lives of my children and grandchildren in a meaningful way. And with my 65th birthday upon us, we'll see if I've stemmed the tide and can still dunk!"

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM and increase the number of circulating stem cells, thereby supporting the natural ability of the body to repair and stay healthy. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/.

About Marques Johnson

Marques Johnson is a basketball analyst for the Milwaukee Bucks on Fox Sports Net. He played college basketball for the UCLA Bruins, won a national championship in 1975 and was the College Player of the Year as a senior. A five-time All-Star, he played seven seasons with Milwaukee before finishing his NBA career with the Los Angeles Clippers and the Golden State Warriors. He is currently a finalist for the NBA Hall of Fame and can still dunk at the age of 65.

*VIDEO (YouTube): https://youtu.be/aGJibMXwmuw

Media Contact:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan, Chief Marketing Officer
(310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

Disclaimer: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the fall of 2021, aims to evaluate the effect of ESCM in cases of heart failure. Forty-five patients who suffered from acute myocardial infarction will be randomly distributed into three groups: i) STEMREGEN® alone, ii) injection of stem cells (SVF), and iii) combined consumption of STEMREGEN® and stem cell injection. The dietary supplement will be provided at a dose of 2 capsules three times a day for 3 to 6 months. Study participants will be evaluated after 1, 3, 6 and 12 months, at which times their NYHA functional classification and echocardiographic parameters will be assessed. The first phase will begin with 15 patients.

"We have had a great deal of success treating patients suffering from advanced heart failure with stem cells," said Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy. "Unfortunately, traditional stem cell therapy utilizing Stroma Vascular Fraction is not widely available. We are hopeful that treating patients with STEMREGEN, a much more cost-effective widely-available therapy, can show similar beneficial health outcomes, and that it can further improve patient outcomes when combined with SVF therapy."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/

About Miguel Garber

Miguel Garber has over 32 years of experience in internal medicine and cardiology, with expertise in regenerative medicine, training and education, and research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Espanola de Medicina Regenerativa y Terapia Celular.

Media Contact:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan
Chief Marketing Officer
(310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

###
Disclaimer: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Drugs and Pharmaceuticals, Free News Articles, Insurance

EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group

SAN FRANCISCO, Calif. -- EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.

As a strategic partner to self-insured employers, health plans and health systems, PSG is an experienced navigator of the complex drug pricing market, and generates more than $4.8 billion in drug cost savings for clients each year.

"The opportunity to continue the next phase of our journey with EPIC is exciting," said Dave Borden, PSG Founder. "For more than 25 years, our dedicated clinicians and consultants have relentlessly advocated for clients, harnessing innovation to deliver the highest standard of pharmacy benefits consulting and technology."

Commenting on the announcement, Scott Schanen, President, EPIC National Employer Consulting, said, "Joining forces with PSG accelerates our ability to establish a new normal amid the dynamic landscape of employee engagement, health and economics. Long regarded as the industry leader in drug cost management, PSG's partnership with EPIC creates value for clients through independent, objective and sustainable solutions and strategies."

Steve Denton, EPIC CEO, added, "The cultural fit between PSG and EPIC has been apparent at every turn. We are collaborating to bring the combined expertise and breadth of service offerings to our clients and look forward to a positive 2021."

Michael Lonergan will continue to serve as PSG President and will lead the charge to develop innovative drug management solutions for U.S. plan sponsors. PSG will operate as "Pharmaceutical Strategies Group - an EPIC company."

About EPIC Brokers & Consultants

EPIC Insurance Brokers & Consultants has more than 2,600 team members operating from more than 80 offices across the U.S., providing Property and Casualty, Employee Benefits, Specialty Programs, and Private Client solutions to EPIC clients. For more information on EPIC, visit: https://epicbrokers.com/.

About Pharmaceutical Strategies Group

PSG is the leading pharmacy intelligence and technology company solving one of healthcare's biggest challenges - rising drug costs. It provides innovative drug management solutions to many of America's largest self-funded employers and health plans, who rely on trusted advisors to improve their financial performance.

Related link: https://www.epicbrokers.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va. -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology (San Antonio, TX), a company that has been exploring the health-related benefits of novel extracts of Nerium oleander for the past 25 years.

Avila Herbals began product development activities in the spring of 2020 and optimized several different proprietary extraction techniques. The company developed the formulation and the products and has scaled manufacturing in anticipation for a launch of several different products. Each product contains a unique extract from the Nerium oleander plant. Phoenix has filed several patent applications based on this work related to SARS-CoV-2 infection and the COVID-19 pandemic.

"We look forward to working with Phoenix Biotechnology. We are committed to developing and manufacturing several new oleander-based products with Phoenix," commented Dr. Richard Obiso, co-owner and CSO of Avila Herbals. "We are thrilled to be able to apply our research and manufacturing expertise to the development of these products."

The agreements support continued manufacturing so that the product can be made available in the United States and internationally. The agreements also cover the development and manufacture of a pharmaceutical, if clinical trials are approved by the US Food and Drug Administration (FDA); although the specific terms of the agreements were not disclosed.

Since Q2 CY2020, Avila Herbals and its partners have invested over $4.5 million dollars into the development and commercialization of these products in the New River Valley of Virginia. Avila has created more than 50 full-time jobs in just a few months to support the development and manufacturing of these products.

"Avila Herbals contributes to the economy of the New River Valley. The company's research and development of the potential health benefits of the extract of Nerium oleander is impressive, and we thank Avila and Phoenix for their commitment to the region and to the Commonwealth," said US Congressman Morgan Griffith.

According to Theresa Obiso, co-owner and CEO of Avila Herbals, "When we began our collaborations, we immediately scaled to meet this need; doing so here in Christiansburg allows us to leverage strong local relationships and build a world-class team."

"Avila Herbals' expansion is a significant win for our region's future and our growing economy," said Virginia Delegate Nick Rush. "Avila is a technology leader that exemplifies the New River Valley's entrepreneurial spirit," Delegate Rush continued. "I wish Avila Herbals much success as it moves forward to becoming one of SWVA's newest technology success stories."

About Avila Herbals

Avila Herbals has created a sustainable agriculture program in the New River Valley of Virginia that focuses on the production of the highest quality botanicals for use in nutraceuticals and botanical pharmaceuticals. The team uses supercritical carbon dioxide extraction as well as novel cryo-ethanol methods, and has launched several botanical preparations. Our passion is sustainable agriculture, organic techniques, and biodynamic farming practices. At Avila Herbals, we work hard to exceed regulatory standards, because we believe in sustainability and great quality. All of our products are manufactured in our GMP facilities.

About Phoenix Biotechnology

Phoenix Biotechnology, Inc. is a San Antonio, Texas-based biotechnology company that was incorporated in Texas in 2003 to develop promising agents from Nerium oleander with minimal or no side effects for targeted therapy in three areas: malignant tumor growth (an extract of Nerium oleander has been found to bind to discrete cellular targets in solid tumors in vitro and in vivo), neurological disorders (ischemic stroke, Alzheimer's disease, and Huntington's disease), and viral diseases. To date, Phoenix has identified potent antiviral activity against Ebola and Marburg viruses, cytomegalovirus, herpes simplex viruses, HIV and HTLV-1, and SARS-CoV-2.

For more information about Avila Herbals, please contact Avila Herbals at info@avilaherbals.com (preferred) or 1-540-808-2314.

On the web: https://avilaherbals.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/20-1028x2p-avila-herbals-300dpi.jpg

Related link: https://avilaherbals.com/

This news story was published by the Neotrope® News Network - all rights reserved.